Lexapro (escitalopram) stays in the body for roughly 6 to 7 days after the final dose in most healthy adults, based on a mean terminal half-life of 27 to 32 hours.
You may be reading this because you are weighing whether to stop, switch, or hold the medication before a surgery, a pregnancy decision, or an upcoming drug test. Each of those situations has different clearance considerations, and the answer depends on your dose, your liver, your genetics, and how long you have been taking it.
If you are coordinating an antidepressant change alongside treatment for substance use or co-occurring depression, our team can review your prescription medications before intake.
Key Takeaways
- Half-life is 27–32 hours. Healthy adults clear most of an escitalopram dose in 5 to 7 days; older adults may take 9 to 10 days.
- Workplace drug tests rarely flag SSRIs. Standard 5- and 10-panel screens do not target Lexapro, and a Medical Review Officer can verify prescription use.
- Withdrawal usually begins within 1 to 7 days of stopping. Tapering slowly under a clinician reduces severity and protects mood stability.
- CYP2C19 genotype matters. Poor metabolizers carry 2 to 3 times higher plasma exposure and may need lower starting doses.
What Lexapro Is and Why Clearance Timing Matters
Lexapro is the brand name for escitalopram, a selective serotonin reuptake inhibitor (SSRI) approved for major depressive disorder and generalized anxiety disorder.
It works by blocking serotonin reuptake at the synapse, gradually raising synaptic serotonin over weeks of dosing.
Clearance timing comes up most often in these situations:
- Planned surgery (bleeding risk)
- Pregnancy or breastfeeding decisions
- Switching to a different antidepressant
- A workplace or pre-admission drug test
- Stopping treatment after a course of therapy
For patients entering residential or outpatient care, accurate medication histories let the clinical team plan a safe transition without interrupting psychiatric stability.
Pharmacokinetics: Half-Life, Steady State, and Active Metabolites
Escitalopram has a mean terminal half-life of about 27 to 32 hours in healthy adults, per the FDA prescribing information.
Steady-state plasma levels are reached in 7 to 10 days of daily dosing.
The liver converts escitalopram into two primary metabolites, S-DCT (S-desmethylcitalopram) and S-DDCT (S-didesmethylcitalopram), via CYP2C19, CYP3A4, and CYP2D6. About 8 to 10% of an oral dose is excreted unchanged in urine, with the rest leaving as metabolites.
Clinicians use a “5 half-lives” rule to estimate when drug levels become clinically negligible. For escitalopram, that translates to roughly 5 to 7 days for most adults and longer for older patients or those with liver impairment.
Detection Windows by Sample Type
| Sample Type | Typical Detection Window | Notes |
| Blood (plasma) | Up to 6 days after last dose | LC-MS detects parent drug and S-DCT metabolite |
| Urine | Up to 7 days after last dose | About 8–10% excreted unchanged; metabolites detectable longer |
| Saliva | 1 to 3 days | Less commonly used; sensitive to dose timing |
| Hair | Up to 90 days | Reflects chronic use; not used for recent dosing |
Will Lexapro Show Up on a Standard Drug Test?
Standard 5- and 10-panel workplace drug screens do not test for SSRIs, so Lexapro almost never produces a positive result on pre-employment or routine random panels.
Immunoassays target classes like amphetamines, cocaine metabolites, opioids, cannabinoids, PCP, and benzodiazepines.
Rare cross-reactivity has been reported, where a structurally similar compound creates a presumptive positive flag. Labs send those samples for confirmatory testing rather than reporting the screen as final.
Confirmatory methods like gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) identify molecular mass and fragmentation patterns. These reliably separate escitalopram and its metabolites from amphetamines or other analytes.
What to Tell an Employer or Medical Review Officer
If you take Lexapro and worry about an unexpected positive, share your prescription documentation with a Medical Review Officer before final reporting. The MRO is a licensed physician who verifies legitimate medication use and updates the result accordingly.
For pre-admission planning, our team coordinates with prescribers to verify prescriptions and avoid surprises. Our guide on finding prescription drug treatment walks through what to expect during intake.
Factors That Change Lexapro Clearance
How long Lexapro stays in your system depends on:
- Age (older adults clear more slowly)
- Liver function (single biggest driver)
- Kidney function (minor effect)
- Dose history and duration of use
- Drug-drug interactions
- CYP2C19 genotype
Reduced hepatic clearance can roughly double the half-life. Other variables stack on top of that baseline shift.
Individual Factors That Slow Escitalopram Clearance
| Factor | Effect on Clearance | Practical Implication |
| Age 65+ | About 50% longer half-life | Full clearance may take 9–10 days |
| Hepatic impairment | Clearance reduced ~37% | Half-life roughly doubles; lower starting doses |
| CYP2C19 poor metabolizer | 2–3x higher exposure | FDA recommends max 10 mg/day |
| CYP2C19 ultrarapid metabolizer | Lower exposure | Higher rate of dose escalation and switching |
| Severe renal impairment | Modestly prolonged | Most clearance is hepatic, not renal |
| Chronic daily use | Steady state in 7–10 days | Detection windows lengthen vs. single doses |
| CYP inhibitors (omeprazole, cimetidine) | Slowed clearance | Drug-drug interaction review recommended |
Combining escitalopram with alcohol or other CNS depressants raises a separate set of risks. Our breakdown on the dangers of mixing alcohol and medication covers what to watch for during a taper.
CYP2C19 Pharmacogenomics: A Closer Look
Escitalopram is predominantly metabolized by CYP2C19, a polymorphic liver enzyme with wide variability across the population.
Pharmacogenomic testing classifies patients into five phenotypes that meaningfully change how the drug clears.
Poor metabolizers carry two non-functional CYP2C19 alleles and clear escitalopram slowly, producing 2 to 3 times higher plasma exposure at the same dose. The FDA escitalopram label recommends a maximum dose of 10 mg per day for known poor metabolizers.
Intermediate metabolizers carry one reduced-function allele and clear the drug somewhat slower than normal.
Normal, rapid, and ultrarapid metabolizers progressively clear faster. A 2025 analysis found that both reduced and increased CYP2C19 activity were associated with higher rates of switching antidepressants, suggesting genotype affects both safety and efficacy.
Why This Matters in 2026
Genotype-guided dosing is now widely available through commercial pharmacogenomic panels. Several integrated health systems run CYP2C19 testing before initiating escitalopram.
For patients with a history of poor SSRI response or significant side effects, testing can shorten the trial-and-error window.
Discontinuation: What Withdrawal Looks Like
Stopping Lexapro abruptly can produce discontinuation symptoms within 1 to 7 days of the last dose.
Common withdrawal symptoms include:
- Dizziness and balance problems
- Paresthesia (the “brain zap” sensation)
- Insomnia and vivid dreams
- Anxiety and irritability
- Nausea and GI upset
- Flu-like aches and headache
- Mood swings or low mood
Symptoms typically peak in the first week and ease over 2 to 4 weeks. A minority of patients experience protracted symptoms lasting months.
Risk rises with longer duration of use, higher daily doses, slower CYP2C19 metabolism, and abrupt cessation. Cross-tapering to another SSRI or SNRI may mute symptoms but should be coordinated with your prescriber.
If you also live with a substance use disorder, abrupt discontinuation can be especially destabilizing. Our dual diagnosis program coordinates psychiatric medication management alongside addiction treatment so taper timing supports both conditions.
How to Taper Safely: Linear vs. Hyperbolic Schedules
Traditional tapering uses linear dose reductions.
For example: 20 mg → 15 mg → 10 mg → 5 mg → 0 mg, spaced 2 to 4 weeks apart.
This works well for short-term users but produces sharper drops at the low end, which is when many people experience the worst withdrawal.
Hyperbolic tapering reduces the dose in proportion to serotonin transporter (SERT) occupancy rather than milligrams. Because the dose-occupancy curve flattens at higher doses, early cuts can be larger while end-of-taper reductions become progressively smaller.
This usually requires liquid escitalopram or compounding pharmacies. A 2022 case report describes hyperbolic schedules that deliver roughly a 10% reduction in SERT occupancy per step, easing the final stages of withdrawal.
Example Hyperbolic Taper (Illustrative, Not Prescriptive)
| Step | Dose | Approximate SERT Occupancy |
| Starting dose | 20 mg | ~85% |
| Step 1 | 10 mg | ~80% |
| Step 2 | 5 mg | ~75% |
| Step 3 | 2.5 mg | ~65% |
| Step 4 | 1.25 mg | ~50% |
| Step 5 | 0.5 mg | ~30% |
| Stop | 0 mg | 0% |
Spacing between steps is typically 2 to 6 weeks and should be symptom-guided. Patients with prior severe withdrawal, long duration of use, or known CYP2C19 poor metabolizer status often need slower steps.
For patients tapering escitalopram inside a structured program, our medical detox track coordinates psychiatric medication adjustments during the early withdrawal window.
Perioperative Planning: Surgery, Bleeding, and Serotonin Syndrome
SSRIs including escitalopram modestly increase bleeding risk, primarily through reduced platelet serotonin uptake.
The clinical question before elective surgery is whether to hold the SSRI. The answer depends on procedure type, bleeding risk, and relapse risk.
For most low-bleeding-risk procedures, continuing Lexapro is reasonable. For high-bleeding-risk surgery like intracranial, spinal, or certain cardiac procedures, some surgeons request a hold of 1 to 2 weeks. Holding requires a slow taper rather than abrupt cessation to avoid withdrawal.
Serotonin syndrome risk rises sharply when escitalopram is combined with:
- Monoamine oxidase inhibitors (MAOIs)
- Linezolid (an antibiotic)
- Methylene blue (used in some surgical procedures)
- High-dose tramadol
- High-dose fentanyl
Surgical and anesthesia teams need a current medication list to avoid these combinations during the perioperative window. If your surgery follows or precedes a residential admission, our residential inpatient program will share medication notes with your surgical team.
Pregnancy, Breastfeeding, and Lactation
The FDA escitalopram label notes a risk of neonatal adaptation syndrome with third-trimester SSRI exposure. Transient symptoms can include jitteriness, feeding difficulty, and respiratory distress.
Persistent pulmonary hypertension of the newborn has been reported but remains uncommon.
Escitalopram passes into breast milk in low concentrations. Most lactation references rate it as compatible with breastfeeding for term, healthy infants.
Decisions weigh untreated maternal depression against medication exposure and should involve obstetrics, psychiatry, and pediatrics.
Switching Antidepressants: Washouts and Cross-Tapers
Switching from Lexapro to another SSRI or SNRI usually involves a brief cross-taper without a strict washout, since serotonin syndrome risk between SSRIs is low.
Common transitions include escitalopram to sertraline, fluoxetine, or venlafaxine.
Switching to or from a monoamine oxidase inhibitor (MAOI) requires a strict 14-day washout in either direction. Fluoxetine, with its long half-life, needs a 5-week washout before starting an MAOI.
Bupropion, mirtazapine, and other non-serotonergic agents can usually be started during a Lexapro taper without strict washout, but timing should match individual response.
Effects vs. Clearance: Two Different Timelines
A common misconception is that once Lexapro is “out of your system,” its effects vanish. In practice, downstream serotonergic adaptations like receptor density changes and neurogenesis effects can persist for weeks after clearance.
This explains why some patients feel stable for 1 to 3 weeks after stopping before delayed withdrawal or symptom return appears. It also explains why dose escalations can take 4 to 6 weeks to show full therapeutic effect.
When tracking your own response, separate the question “Has the drug cleared?” (days) from “Have the clinical effects resolved or built up?” (weeks to months).
Speak With Our Admissions Team
If you are weighing a Lexapro change alongside addiction treatment, our admissions coordinators handle medication reviews, prescriber outreach, and psychiatric handoffs before you arrive. Decisions about your taper stay with your treatment team, not the program timeline.
Call 866-890-9573 for a confidential conversation.
Frequently Asked Questions
How long after my last dose will I stop feeling Lexapro’s effects?
Plasma levels fall by roughly half each day and reach clinically negligible levels in 5 to 7 days for most adults. Downstream effects on serotonin signaling can persist for several more weeks, and discontinuation symptoms may begin within 1 to 7 days.
Can I take a single dose without it being detectable?
A single dose still produces measurable escitalopram in blood and urine for several days. Detection windows are shorter than with chronic dosing but not zero, and hair testing can pick up even occasional use for up to 90 days.
Do I need to tell my employer I take Lexapro?
Standard pre-employment drug panels do not screen for SSRIs, so disclosure is generally not required for routine testing. If a panel is unexpectedly flagged, share the prescription with the Medical Review Officer rather than your direct employer.
How long should I wait between stopping Lexapro and starting an MAOI?
The FDA-recommended washout is 14 days in either direction to avoid serotonin syndrome. Confirm timing with your prescriber, since some related medications need longer windows.
Will pharmacogenomic testing help me decide my dose?
CYP2C19 testing can identify poor or ultrarapid metabolizers, both of which change exposure and side-effect risk. Clinicians integrate genotype with liver function, drug interactions, and prior response before adjusting dose.
Is hyperbolic tapering available everywhere?
Hyperbolic tapers often require liquid escitalopram or compounded micro-doses, which are accessible through specialty pharmacies. Many primary care prescribers refer to psychiatry for slow, symptom-guided tapers using this approach.
Can I speed up Lexapro elimination after an accidental overdose?
In emergencies, call 911 or Poison Control immediately. Activated charcoal may help if given soon after ingestion in a clinical setting, but there are no safe outpatient methods to accelerate elimination.
Coordinating Medication Management During Admission
If you are considering admission to a treatment program and currently take Lexapro, share your full medication list, including dose, duration, and prescriber contact, during your intake conversation.
Our admissions coordinators verify prescriptions, flag interactions, and arrange psychiatric follow-up during your stay. Antidepressant taper decisions stay with your treatment team, not the program timeline.
To start a confidential conversation, verify your insurance or call 866-890-9573 to speak with our admissions team.
